Wedbush Issues Positive Forecast for Biogen Earnings

Biogen Inc. (NASDAQ:BIIB) – Research analysts at Wedbush raised their Q2 2025 EPS estimates for shares of Biogen in a research report issued to clients and investors on Wednesday, April 16th. Wedbush analyst L. Chico now expects that the biotechnology company will earn $4.21 per share for the quarter, up from their previous estimate of $3.98. The consensus estimate for Biogen’s current full-year earnings is $15.83 per share. Wedbush also issued estimates for Biogen’s Q3 2025 earnings at $4.12 EPS, Q4 2025 earnings at $3.87 EPS, FY2025 earnings at $15.71 EPS, Q3 2026 earnings at $4.33 EPS, FY2028 earnings at $20.48 EPS and FY2029 earnings at $21.14 EPS.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share for the quarter, topping the consensus estimate of $3.43 by $0.01. Biogen had a return on equity of 14.98% and a net margin of 16.87%.

Several other research firms have also recently issued reports on BIIB. Morgan Stanley lowered their price objective on shares of Biogen from $157.00 to $152.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 9th. Sanford C. Bernstein began coverage on Biogen in a report on Tuesday, February 11th. They set a “market perform” rating and a $160.00 price objective on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Biogen in a research report on Wednesday. Truist Financial dropped their price target on Biogen from $220.00 to $210.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. Finally, Canaccord Genuity Group decreased their price objective on Biogen from $298.00 to $265.00 and set a “buy” rating for the company in a report on Thursday, February 13th. Eighteen research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat.com, Biogen currently has a consensus rating of “Hold” and an average price target of $213.15.

Biogen Stock Up 2.9 %

Shares of BIIB opened at $118.61 on Friday. The firm has a market capitalization of $17.36 billion, a P/E ratio of 10.60, a P/E/G ratio of 1.51 and a beta of 0.06. Biogen has a 12-month low of $110.04 and a 12-month high of $238.00. The firm has a fifty day moving average price of $134.29 and a 200-day moving average price of $151.69. The company has a current ratio of 1.35, a quick ratio of 0.90 and a debt-to-equity ratio of 0.27.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Grove Bank & Trust boosted its holdings in Biogen by 255.2% in the first quarter. Grove Bank & Trust now owns 444 shares of the biotechnology company’s stock valued at $61,000 after purchasing an additional 319 shares during the last quarter. Grimes & Company Inc. boosted its stake in shares of Biogen by 131.7% in the first quarter. Grimes & Company Inc. now owns 59,334 shares of the biotechnology company’s stock worth $8,119,000 after buying an additional 33,721 shares during the last quarter. QRG Capital Management Inc. grew its holdings in Biogen by 55.1% during the first quarter. QRG Capital Management Inc. now owns 4,039 shares of the biotechnology company’s stock worth $553,000 after acquiring an additional 1,435 shares during the period. Janney Montgomery Scott LLC raised its position in Biogen by 45.6% during the first quarter. Janney Montgomery Scott LLC now owns 17,941 shares of the biotechnology company’s stock valued at $2,455,000 after acquiring an additional 5,620 shares in the last quarter. Finally, Bank Pictet & Cie Europe AG acquired a new position in Biogen in the first quarter valued at approximately $221,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Insider Activity

In other Biogen news, Director Stephen A. Sherwin sold 8,760 shares of Biogen stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $150.02, for a total transaction of $1,314,175.20. Following the completion of the sale, the director now directly owns 11,318 shares in the company, valued at approximately $1,697,926.36. The trade was a 43.63 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.